Search Clinical Trials in the EU

Duration

11-15 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

81-100 of 306 trials

Dostarlimab for Advanced Cancer with dMMR/MSI

We are studying whether the immunotherapy dostarlimab can help patients with advanced non-colorectal and non-endometrial cancers live longer compared to standard treatments. This trial focuses on those with specific genetic markers in their tumors.

dMMR/MSI Cancer>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesOncology

Chronic Rhinosinusitis: Mepolizumab and Nasal Polypectomy Study

We are investigating whether combining Mepolizumab with in-office nasal polypectomy can improve quality of life for patients with chronic rhinosinusitis. The study will assess symptom relief and safety over time.

Chronic Rhinosinusitis with Nasal Polyps6-12 monthsMonitoring phase (IV)11-15 visits No Placebo Standard MedicinesAllergologyOtolaryngology

Sparsentan for Pediatric Kidney Diseases

We are studying a new oral treatment for children with certain kidney diseases to see if it is safe and effective. The trial will also evaluate how well children tolerate the medication and its impact on kidney function.

Proteinuric Glomerular Diseases>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteNephrologyPediatrics

Giant Cell Arteritis: Stopping Tocilizumab

We are comparing immediate versus gradual stopping of tocilizumab in patients with giant cell arteritis. The goal is to see which method helps prevent relapses and improves quality of life.

Giant Cell Arteritis1-2 yearsConfirmation phase (III)11-15 visits No Placebo Standard MedicinesRheumatology

Pulmonary Arterial Hypertension: Treprostinil Palmitil Inhalation Powder

We are studying the long-term safety and effects of an inhalation powder for people with pulmonary arterial hypertension. This research aims to see if it improves exercise capacity and overall health.

Pulmonary Arterial Hypertension1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteCardiologyPulmonology

Fosigotifator for Vanishing White Matter Disease

We are exploring the safety and tolerability of Fosigotifator in adults and children with Vanishing White Matter Disease. This study aims to understand how the body handles this new treatment.

Vanishing White Matter Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteNeurology

Early Breast Cancer: Elacestrant and Ribociclib Study

We are testing a new treatment combination of elacestrant and ribociclib for patients with hormone-sensitive early breast cancer. The goal is to see if this combination works better than standard therapies before surgery.

Hormone Receptor Positive HER2 Negative Breast Cancer6-12 monthsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesGynecology and ObstetricsOncology

Systemic Sclerosis: Anifrolumab Treatment Study

We are investigating whether Anifrolumab can improve symptoms and lung function in adults with systemic sclerosis. This study compares the new treatment to a placebo to see how well it works.

Systemic SclerosisImmune System DiseasesInterstitial Lung Disease>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteDermatologyRheumatology

HMB-001 for Glanzmann Thrombasthenia

We are investigating a new treatment to see if it is safe and can help reduce bleeding in people with Glanzmann Thrombasthenia. This study will also look at how the body processes the medication and its effects on quality of life.

Glanzmann's Disease1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematology

Achondroplasia: TransCon CNP Treatment for Infants

We are investigating the safety and growth effects of weekly injections of TransCon CNP in infants with achondroplasia. This study aims to understand how the treatment may help with growth and development.

Achondroplasia1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementEndocrinologyPediatrics

Cytomegalovirus Treatment: Letermovir and Valganciclovir Combination

We are studying whether a combination of letermovir and valganciclovir helps kidney transplant recipients with CMV infections achieve better viral response than valganciclovir alone.

Cytomegalovirus InfectionKidney Transplant>2 yearsConfirmation phase (III)11-15 visits Investigational MedicinesInfectious DiseasesNephrology

Plaque Psoriasis in Teens: Deucravacitinib Study

We are evaluating a new medication for adolescents with moderate to severe plaque psoriasis to see if it helps improve their skin condition compared to a placebo. The study also looks at safety and how patients feel about their treatment.

Plaque Psoriasis1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteAllergologyDermatology

MB-CART2019.1 Therapy for Pediatric B-Cell Neoplasms

We are studying how safe and effective MB-CART2019.1 is for children and teens with relapsed or refractory B-cell cancers. This research aims to find better treatment options for those who haven't responded to other therapies.

Refractory or Recurrent B-cell Lymphoma1-2 yearsEfficacy phase (II)11-15 visits No Placebo Investigational MedicinesOncologyPediatrics

Giant Cell Arteritis: Etanercept vs. Methotrexate

We are comparing two treatments, etanercept and methotrexate, to see which is more effective for patients with giant cell arteritis. The goal is to find out which treatment helps achieve remission and prevents complications better.

Giant Cell ArteritisEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Standard MedicinesInfectious DiseasesRheumatology

Localized Ocular Melanoma: IDE196 Treatment Study

We are testing the investigational drug IDE196 to see if it can shrink tumors in patients with localized ocular melanoma before surgery. The study aims to evaluate its safety and effectiveness in improving treatment outcomes.

Uveal MelanomaEfficacy phase (II)11-15 visits No Placebo Investigational MedicinesOncologyOphthalmology

Crohn's Disease: TAK-279 Oral Medication

We are studying a new oral treatment for people with moderately to severely active Crohn's disease. The trial aims to see if it helps improve symptoms and overall health compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementGastroenterologyInternal Medicine

ALK Positive Non-Small Cell Lung Cancer: Chemotherapy Plus Lorlatinib

We are studying a combination of chemotherapy and Lorlatinib for patients with ALK positive NSCLC who have had disease progression outside the brain. The goal is to see if this treatment improves outcomes compared to past therapies.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard Medicines Partially RemoteOncology

Advanced Solid Tumors: AZD3470 Study

We are testing a new drug, AZD3470, for patients with advanced solid tumors lacking the MTAP gene. The study aims to evaluate its safety and effectiveness, both alone and with other cancer treatments.

Advanced Metastatic Solid Tumors (MTAP Deficient)Safety phase (I)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteOncology

Ulcerative Colitis: TAK-279 Oral Medication

We are testing the effectiveness of TAK-279 for people with moderately to severely active ulcerative colitis. The study aims to see if it helps achieve remission and improves symptoms compared to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementGastroenterologyInternal Medicine

Alectinib Dosing: Standard vs. Personalized Approach

We are comparing standard alectinib dosing to a personalized dosing method based on blood levels for patients with specific alectinib concentrations. The goal is to see if personalized dosing improves treatment outcomes and safety.

ALK Positive Non-Small Cell Lung Cancer1-2 yearsMonitoring phase (IV)11-15 visits No Placebo Standard MedicinesOncologyPulmonology

Search Clinical Trials in the European Union